Form 4: Theravance Biopharma Executive Aine Miller Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
Aine Miller, SVP at Theravance Biopharma, disposed of 5,201 ordinary shares to cover tax obligations related to vesting restricted stock units.
Summary
- On May 20, 2024, Aine Miller, SVP at Theravance Biopharma, disposed of 5,201 ordinary shares.
- The shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
- The transaction was conducted with the issuer and did not involve an open market transaction.
- Following the transaction, Miller beneficially owns 165,833 ordinary shares.
Sentiment
Score: 5
Explanation: The filing reflects a routine transaction for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential sentiment.
Related Party Transactions
- The share withholding transaction was with the issuer to satisfy tax obligations.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of transaction: Disposal of ordinary shares. |
| 05/22/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.